Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13329593 | 1.00 | HRH1 (0.38) | HRH1CHRM3KCNH2CHRM2CHRM1 | |
| SCHEMBL4742969 | 1.00 | HRH1 (0.38) | HRH1CHRM3KCNH2CHRM2CHRM1 | |
| SCHEMBL4783525 | 0.99 | HRH1 (0.39) | HRH1CHRM3KCNH2CHRM2CHRM1 | |
| SCHEMBL4742510 | 0.97 | HRH1 (0.39) | HRH1CHRM3KCNH2CHRM2CHRM1 | |
| SCHEMBL1109886 | 0.95 | HRH1 (0.35) | HRH1CHRM3KCNH2CHRM2CHRM1 | |
| SCHEMBL1109891 | 0.95 | CHRM2 (0.37) | HRH1CHRM3KCNH2CHRM2CHRM1 | |
| SCHEMBL1109893 | 0.95 | CHRM2 (0.37) | HRH1CHRM3KCNH2CHRM2CHRM1 | |
| SCHEMBL1109884 | 0.94 | HRH1 (0.35) | HRH1CHRM3KCNH2CHRM2CHRM1 | |
| Bromide SCHEMBL2877676 | 0.94 | CHRM2 (0.36) | HRH1CHRM3KCNH2CHRM2CHRM1 | |
| Bromide SCHEMBL2877682 | 0.94 | CHRM2 (0.36) | HRH1CHRM3KCNH2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | ARGENTA DISCOVERY LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113540-A1 | Azole and Thiazole Derivatives and Their Use | CHRM3, CHRM2, CHRM1 | HRH1 178/4885CHRM3 1/4885KCNH2 784/4885 |
| US-20120277275-A1 | AZOLE AND THIAZOLE DERIVATIVES AND THEIR USE | CHRM3, GPR65, GPR34 | HRH1 183/4885CHRM3 1/4885KCNH2 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.